Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
Double Blind, Double-dummy, Randomised, Placebo Controlled Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects
This study ended early.
In GöttingenA Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia
Read the official source — NCT00210548This study evaluated the safety and effectiveness of paliperidone palmitate for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedA Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
Read the official source — NCT00490971Researchers compared Paliperidone ER, placebo and Olanzapine to find out how the approaches affected how long people remain free of a new mood episode in people with bipolarity type I.
This study has finished and is no longer accepting participants.
Multiple locations, including ScottsdaleResearchers studied Paliperidone palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including HuzhouA Placebo- and Active-Controlled Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Subjects With Major Depressive Disorder (DriveSaFe2)
This study has finished and is no longer accepting participants.
In LeidenThis study evaluated the safety and effectiveness of Basmisanil for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveA Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveA Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixA Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
Read the official source — NCT00309686A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stabilizers in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedResearchers compared ALKS 9072 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.